Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Chart Review and a Prospective Study of the POmalidomide Plus LoW Dose Dexamethasone Efficacy in Relapsed/ ReFractory Multiple Myeloma Patients Under Real-Life Conditions,

NCT03353545 is registered in ClinicalTrials.gov with Genesis Pharma S.A. as lead sponsor.

NCT NCT03353545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03353545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Chart Review and a Prospective Study of the POmalidomide Plus LoW Dose Dexamethasone Efficacy in Relapsed/ ReFractory Multiple Myeloma Patients Under Real-Life Conditions,
Lead sponsor
Genesis Pharma S.A.
Phase
Observational
Overall status
Completed
Start date
November 16, 2017
Completion date
February 28, 2020
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapse/refractory multiple myeloma